Breaking News

TAP Biosystems Approves Sartorius Takeover

November 22, 2013

Expands Sartorius’ bioprocess portfolio in fermentation

The shareholders of TAP Biosystems Group have approved Sartorius Stedim Biotech’s takeover offer valued at approximately $44 million. The transaction is expected to close at the end of the year.
 
The acquisition expands Sartorius’ bioprocess portfolio in the area of fermentation, particularly in the early phases of product and process development. TAP Biosystems, headquartered in Royston, UK, specializes in the design and development of small scale, multi-parallel fermentation and cell culture systems for biopharmaceutical applications. TAPs’ portfolio includes automated cell processing systems and other benchtop equipment. TAP Biosystems generated sales revenue of approximately $35 million in 2012-13 and has approximately 160 employees worldwide.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments